Prescient Therapeutics (ASX:PTX) share price flat after trial success news

Shares in the clinical stage oncology company have clawed back some ground after falling in early trade this morning

A health professional sits contemplating in the corridor of a hospital.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Prescient Therapeutics Ltd (ASX: PTX) share price is having a lacklustre day, despite a positive readout on its PTX-100 trial.

Prescient shares dipped into the red in morning trade. However, at the time of writing they are exchanging hands for 22 cents a piece, the same as yesterday's closing price.

Let's take a look at what Prescient released this morning.

Quick refresher on Prescient Therapeutics

Prescient is a clinical stage oncology company that researches, develops and commercialises new cancer treatments.

It has expertise in the treatment of myeloma, pancreatic and breast cancer. It also collaborates with larger players to develop its proprietary products.

Prescient has a market capitalisation of $138 million at the time of writing.

PTX-100 basket trial results

Prescient released the readouts from its PTX-100 phase 1b basket trial earlier today. The purpose of a phase 1b trial is to determine the optimal safe dose for a new therapy.

As such, the trial examined the safety of the PTX-100 compound, which Prescient is studying for solid and haematological tumours.

In the trial, PTX-100 "exhibited an excellent safety profile … up to and including the highest dose", with no adverse events "deemed serious, nor related to PTX-100".

Another takeout is that two patients also received a "clinical benefit" after a run of failed prior treatments for their condition.

Both patients benefitted from "symptomatic relief" and a "reduction in cancer burden with no disease progression".

Prescient now intends to begin a cohort study to develop PTX-100 as a monotherapy, hoping to create a "potentially shorter regulatory path" for the compound.

Investors can expect further readouts from this study in the coming quarter, as per the company.

Prescient share price snapshot

The Prescient Therapeutics share price has posted a year-to-date return of about 215%, extending the previous 12 month's return of 268%.

These returns have far outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of 23% over the past year.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »